Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Amino acid infusion study aims to unlock fatty liver secrets

NCT ID NCT06240039

Knowledge-focused Sponsor: University of Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how amino acids trigger the liver to release hormones in healthy people and those with non-alcoholic fatty liver disease. Researchers will give amino acid infusions with or without a drug that blocks natural hormone production. By comparing the results, they hope to understand why liver hormone levels are often high in fatty liver disease. The study involves 30 participants and uses MRI scans to measure liver fat.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amino acid infusion
What this could lead to
If successful, this study could reveal why liver hormone levels are high in fatty liver disease, pointing toward new treatment targets.
What could go wrong
This is a small, early-stage study (30 participants) that only measures short-term effects. It may not translate into treatments or apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Group 1: (Lean controls) Inclusion Criteria: * Male or female between 25-65 years of age at time of screening * Body mass index of 18.6-25 kg/m2 Exclusion Criteria: * Contraindications for MRI-scan * Severe liver disease (estimated by FIB4 score \> 3.25) * Type 2 diabetes according to ADA criteria * Significant history of alcoholism or drug/chemical abuse as per investigators judgement * Amino acid related diseases * Kidney disease * Cardiac problems * Cancer within the past 1 year * Anemia * Pregnancy or breast feeding * Smoking * Any medicine, acute illness (within the last two weeks) or other circumstances that in the opinion of the investigator might endanger the participants' safety or compliance with the protocol Group 2 (individuals with hepatic steatosis): Inclusion Criteria: * Male or female between 25-65 years of age at time of screening * Body mass index of 25-40 kg/m2 * Hepatic non-alcoholic steatosis verified by liver biopsy, fibroscan or ultrasound Exclusion Criteria: * Contraindications for MRI-scan * Severe liver disease (estimated by FIB4 score \> 3.25) * Type 2 diabetes according to ADA criteria * Significant history of alcoholism or drug/chemical abuse as per investigators judgement * Amino acid related diseases * Kidney disease * Cardiac problems * Cancer within the past 1 year * Anemia * Pregnancy or breast feeding * Smoking * Any medicine, acute illness (within the last two weeks) or other circumstances that in the opinion of the investigator might endanger the participants' safety or compliance with the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-alcoholic fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-alcoholic fatty liver disease Obesity

Contacts and locations

Locations

  • Bispebjerg University Hospital

    Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.